A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Inclusion Criteria

1. Have a Body Mass Index (BMI) ≥35 kilogram/square meter (kg/m²) at screening.
2. Have had stable body weight (±5%) during the 90 days preceding screening.
3. Have been diagnosed with Type 2 Diabetes (T2D).
4. Have been on a stable treatment of metformin only at least 90 days preceding screening and between screening and randomization with the minimum effective dose of ≥1500 milligram (mg)/day.

Exclusion Criteria:

1. Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
2. Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months prior to screening.
3. Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
4. Have a prior or planned surgical treatment for obesity.
5. Use products intended for weight loss including prescription drugs, over the counter (OTC) drugs, and herbal preparations, within 3 months prior to screening.
6. Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliter/min (mL/min)/1.73 m².
7. Have any of the following cardiovascular (CV) conditions within 2 months prior to screening.

1. acute myocardial infarction.
2. cerebrovascular accident (stroke).
3. unstable angina .
4. hospitalization due to congestive heart failure, or
5. coronary artery revascularization.
6. Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.
7. Have a history of chronic or acute pancreatitis.